Assessing heart damage in young cancer survivors
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
University of California, San Diego · NCT04262830
This study is trying to find out if heart damage can be detected early in young cancer survivors who received certain chemotherapy treatments, to help prevent future heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 13 Years to 39 Years |
| Sex | All |
| Sponsor | University of California, San Diego (other) |
| Drugs / interventions | doxorubicin |
| Locations | 1 site (San Diego, California) |
| Trial ID | NCT04262830 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the cardiotoxic effects of anthracycline chemotherapy in pediatric cancer survivors. It aims to identify imaging markers of cardiac injury and dysfunction using cardiac MRI and other assessments. By examining a cohort of adolescents and young adults who were treated for cancer, the study seeks to develop improved diagnostic tests and treatment strategies to predict heart failure risk. The goal is to enhance early detection of cardiotoxicity before significant heart function changes occur.
Who should consider this trial
Good fit: Ideal candidates are English and Spanish speaking individuals aged 13-39 who were diagnosed with cancer before age 22 and treated with anthracycline therapy at least two years prior.
Not a fit: Patients with contraindications to cardiac MRI or significant congenital heart disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools for early detection of heart issues in young cancer survivors, potentially preventing heart failure.
How similar studies have performed: Other studies have explored similar imaging techniques for assessing cardiotoxicity, indicating a growing interest in this area, though this specific approach may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * English and Spanish speaking male and female subjects, ages 13-39 years old * Diagnosis of cancer at age \<22 years * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior. Exclusion Criteria: * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants. * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia. * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus). * Pregnancy (at the time of enrollment).
Where this trial is running
San Diego, California
- Rady Children's Hospital — San Diego, California, United States (RECRUITING)
Study contacts
- Principal investigator: Hari Narayan, MD — University of California San Diego, Rady Children's Hospital
- Study coordinator: Hari Narayan, MD
- Email: hnarayan@rchsd.org
- Phone: 8589665855 / 8589331718
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiotoxicity, Pediatric Cancer, Heart Failure